Coverage
-
October 29, 2018
A California federal judge has dismissed two of 23andMe's counterclaims in a dispute with its insurer over a class settlement linked to complaints that the DNA tester violated regulations by providing customers with medical information, saying it wasn't clear that the insurer misbehaved regarding the approval of a settlement.
7 other articles on this case.
View all »